Loading...

Michael Kasperkiewicz

TitleAssociate Professor Of Clinical-Med Only
InstitutionUniversity of Southern California
DepartmentDermatology
Address1520 San Pablo Street
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Payne AS, Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Amagai M. Correction: Paraneoplastic autoimmune multiorgan syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology. Nat Rev Dis Primers. 2018 May 11; 4:18032. PMID: 29749393.
      View in: PubMed
    2. Payne AS, Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Amagai M. Authors' reply: Paraneoplastic autoimmune multi-organ syndrome is a distinct entity from traditional pemphigus subtypes. Nat Rev Dis Primers. 2018 Feb 22; 4:18013. PMID: 29469088.
      View in: PubMed
    3. Kasperkiewicz M, Schmidt E, Ludwig RJ, Zillikens D. Targeting IgE Antibodies by Immunoadsorption in Atopic Dermatitis. Front Immunol. 2018; 9:254. PMID: 29520268.
      View in: PubMed
    4. Kasperkiewicz M, Mook SC, Knuth-Rehr D, Vorobyev A, Ludwig RJ, Zillikens D, Muck P, Schmidt E. IgE-Selective Immunoadsorption for Severe Atopic Dermatitis. Front Med (Lausanne). 2018; 5:27. PMID: 29484297.
      View in: PubMed
    5. Niebuhr M, Kasperkiewicz M, Maass S, Hauenschild E, Bieber K, Ludwig RJ, Westermann J, Kalies K. Evidence for a contributory role of a xenogeneic immune response in experimental epidermolysis bullosa acquisita. Exp Dermatol. 2017 Dec; 26(12):1207-1213. PMID: 28887841.
      View in: PubMed
    6. Bieber K, Ernst AL, Tukaj S, Holtsche MM, Schmidt E, Zillikens D, Ludwig RJ, Kasperkiewicz M. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Exp Dermatol. 2017 Dec; 26(12):1248-1252. PMID: 28500685.
      View in: PubMed
    7. Kasperkiewicz M, Kalies K, Pagel R, Bieber K, Zillikens D, Ludwig RJ. CCL3/MIP1a represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisita. J Dermatol Sci. 2017 Nov; 88(2):248-250. PMID: 28711238.
      View in: PubMed
    8. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017 May 11; 3:17026. PMID: 28492232.
      View in: PubMed
    9. Jascholt I, Lai O, Zillikens D, Kasperkiewicz M. Periodontitis in oral pemphigus and pemphigoid: A systematic review of published studies. J Am Acad Dermatol. 2017 May; 76(5):975-978.e3. PMID: 28038889.
      View in: PubMed
    10. Tukaj S, Görög A, Kleszczynski K, Zillikens D, Kárpáti S, Kasperkiewicz M. Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformis. J Steroid Biochem Mol Biol. 2017 10; 173:23-27. PMID: 27760369.
      View in: PubMed
    11. Tukaj S, Bieber K, Kleszczynski K, Witte M, Cames R, Kalies K, Zillikens D, Ludwig RJ, Fischer TW, Kasperkiewicz M. Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation. J Invest Dermatol. 2017 Feb; 137(2):341-349. PMID: 27659253.
      View in: PubMed
    12. Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E, Zillikens D, Ludwig RJ. Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. J Invest Dermatol. 2016 Jan; 136(1):24-33. PMID: 26763420.
      View in: PubMed
    13. Kasperkiewicz M, Orosz I, Abeck D, Koletzko S, Ruzicka T, Sárdy M. Childhood epidermolysis bullosa acquisita with underlying coeliac disease. Acta Derm Venereol. 2015 Nov; 95(8):1013-4. PMID: 25824338.
      View in: PubMed
    14. Kasperkiewicz M, Platkowska A, Zalewska A, Zillikens D. Heat shock protein 90 inhibition: A potential double- or triple-edged sword in the treatment of mucous membrane pemphigoid. Med Hypotheses. 2015 Oct; 85(4):412-4. PMID: 26152650.
      View in: PubMed
    15. Tukaj S, Zillikens D, Kasperkiewicz M. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases. Exp Dermatol. 2015 Aug; 24(8):567-71. PMID: 25980533.
      View in: PubMed
    16. Tukaj S, Hellberg L, Ueck C, Hänsel M, Samavedam U, Zillikens D, Ludwig RJ, Laskay T, Kasperkiewicz M. Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita. Exp Dermatol. 2015 Jun; 24(6):471-3. PMID: 25739426.
      View in: PubMed
    17. Kleszczynski K, Zwicker S, Tukaj S, Kasperkiewicz M, Zillikens D, Wolf R, Fischer TW. Melatonin compensates silencing of heat shock protein 70 and suppresses ultraviolet radiation-induced inflammation in human skin ex vivo and cultured keratinocytes. J Pineal Res. 2015 Jan; 58(1):117-26. PMID: 25424643.
      View in: PubMed
    18. Kasperkiewicz M, Süfke S, Schmidt E, Zillikens D. IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol. 2014 Dec; 150(12):1350-1. PMID: 25271706.
      View in: PubMed
    19. Hirose M, Tiburzy B, Ishii N, Pipi E, Wende S, Rentz E, Nimmerjahn F, Zillikens D, Manz RA, Ludwig RJ, Kasperkiewicz M. Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita. J Invest Dermatol. 2015 Mar; 135(3):768-775. PMID: 25330299.
      View in: PubMed
    20. Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D, Schmidt E. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol. 2014 Nov; 71(5):1018-20. PMID: 25437968.
      View in: PubMed
    21. Tukaj S, Tiburzy B, Manz R, de Castro Marques A, Orosz A, Ludwig RJ, Zillikens D, Kasperkiewicz M. Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Exp Dermatol. 2014 Aug; 23(8):585-90. PMID: 24961936.
      View in: PubMed
    22. Tukaj S, Grüner D, Zillikens D, Kasperkiewicz M. Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes. Cell Stress Chaperones. 2014 Nov; 19(6):887-94. PMID: 24796797; PMCID: PMC4389849.
    23. Tukaj S, Zillikens D, Kasperkiewicz M. Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. J Inflamm (Lond). 2014 Apr 02; 11(1):10. PMID: 24694060; PMCID: PMC3976086.
    24. Kasperkiewicz M, Tukaj S, Gembicki AJ, Silló P, Görög A, Zillikens D, Kárpáti S. Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis. Cell Stress Chaperones. 2014 Nov; 19(6):837-43. PMID: 24643797; PMCID: PMC4389843.
    25. Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Broad requirement for terminal sialic acid residues and Fc?RIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol. 2014 May; 44(5):1444-53. PMID: 24505033.
      View in: PubMed
    26. Kasperkiewicz M, Kowalewski C, Jablonska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014 Apr; 70(4):780-7. PMID: 24472428.
      View in: PubMed
    27. Tukaj S, Kleszczynski K, Vafia K, Groth S, Meyersburg D, Trzonkowski P, Ludwig RJ, Zillikens D, Schmidt E, Fischer TW, Kasperkiewicz M. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. PLoS One. 2013; 8(7):e70496. PMID: 23936217.
      View in: PubMed
    28. van Beek N, Rentzsch K, Probst C, Komorowski L, Kasperkiewicz M, Fechner K, Bloecker IM, Zillikens D, Stöcker W, Schmidt E. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis. 2012 Aug 09; 7:49. PMID: 22876746; PMCID: PMC3533694.
    29. Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial. 2012 Aug; 16(4):311-20. PMID: 22817118.
      View in: PubMed
    30. Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, von Wussow P, Hertl M, Zillikens D, Freivogel K, Dörner T, Schmidt E. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012 Oct; 10(10):727-32. PMID: 22577946.
      View in: PubMed
    31. Kasperkiewicz M, Nimmerjahn F, Wende S, Hirose M, Iwata H, Jonkman MF, Samavedam U, Gupta Y, Möller S, Rentz E, Hellberg L, Kalies K, Yu X, Schmidt E, Häsler R, Laskay T, Westermann J, Köhl J, Zillikens D, Ludwig RJ. Genetic identification and functional validation of Fc?RIV as key molecule in autoantibody-induced tissue injury. J Pathol. 2012 Sep; 228(1):8-19. PMID: 22430937.
      View in: PubMed
    32. Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012 Jan-Feb; 30(1):84-94. PMID: 22137231.
      View in: PubMed
    33. Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012 Feb; 45(1):55-70. PMID: 21923615.
      View in: PubMed
    34. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep; 65(3):552-8. PMID: 21641080.
      View in: PubMed
    35. Kasperkiewicz M, Dähnrich C, Probst C, Komorowski L, Stöcker W, Schlumberger W, Zillikens D, Rose C. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. J Am Acad Dermatol. 2012 Apr; 66(4):583-8. PMID: 21840083.
      View in: PubMed
    36. Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM, Somlai C, Westermann J, Schmidt E, Zillikens D, Ludwig RJ, Orosz A. Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood. 2011 Jun 09; 117(23):6135-42. PMID: 21490339.
      View in: PubMed
    37. Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, Reich K, Ludwig RJ, Zillikens D. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol. 2011 Jan; 127(1):267-70, 270.e1-6. PMID: 20970174.
      View in: PubMed
    38. Ludwig RJ, Recke A, Bieber K, Müller S, Marques Ade C, Banczyk D, Hirose M, Kasperkiewicz M, Ishii N, Schmidt E, Westermann J, Zillikens D, Ibrahim SM. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol. 2011 Jan; 131(1):167-76. PMID: 20720563.
      View in: PubMed
    39. Kasperkiewicz M, Meier M, Zillikens D, Schmidt E. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology. 2010; 220(3):259-63. PMID: 20130384.
      View in: PubMed
    40. Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol. 2009 Dec; 6(4):270-80. PMID: 20025595.
      View in: PubMed
    41. Bieber K, Sun S, Ishii N, Kasperkiewicz M, Schmidt E, Hirose M, Westermann J, Yu X, Zillikens D, Ludwig RJ. Animal models for autoimmune bullous dermatoses. Exp Dermatol. 2010 Jan; 19(1):2-11. PMID: 19702839.
      View in: PubMed
    42. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007 Oct; 33(1-2):67-77. PMID: 18094948.
      View in: PubMed